Ranked by number of R&D employees in 2020
Published April 26, 2021. Sources: interviews with representatives of biotech firms below and BIV research. Other firms may have ranked but did not respond to information requests by deadline.
| Rank '21 | Company | Top local executive(s) | Areas of research | Ownership | Year founded | No. staff globally '20/'19 | No. B.C. staff '20/'19 | No. R&D staff '20/'19 |
|---|---|---|---|---|---|---|---|---|
|
1
|
Stemcell Technologies Inc |
Allen Eaves, president and CEO |
Provides cell culture media, cell separation tools and accessory reagents for cell biology research, including stem cell biology, regenerative medicine, immunology and cancer research |
Privately held |
1993 |
1,377 |
1,057 |
205 |
|
2
|
Kardium Inc |
Doug Goertzen, president and COO, Kevin Chaplin, CEO |
Cardiovascular |
Privately held |
2007 |
185 |
180 |
150 |
|
3
|
AbCellera |
Carl Hansen, president and CEO |
Searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease |
Public |
2012 |
206 |
174 |
136 |
|
4
|
Zymeworks Inc |
Ali Tehrani, president and CEO |
Antibody and protein therapeutics development with a primary focus in oncology |
NYSE:ZYME |
2003 |
369 |
212 |
123 |
|
5
|
Amgen British Columbia Inc |
John Delaney, executive director of research |
Antibody therapeutics for the treatment of cancer, inflammation and infectious diseases |
Nasdaq:AMGN |
1980 |
24,000 |
NP |
95 |
Want access to the full list and database?
Upgrade to a paid subscription.
To get unlimited access to all of our online features, upgrade today.